Bortezomib in Patients With Chronic Graft Versus Host Disease

Phase 1 Completed 16 enrolled Mehrdad Abedi, MD Millennium Pharmaceuticals, Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

This study will investigate whether bortezomib can control the immune system and can be used to treat GVHD. Bortezomib has been used with not too many serious side effects in patients with multiple myeloma who will undergo transplant and also for acute graft versus host disease.

Timeline

Start: 2012-07
Primary completion: 2018-04-09
Completion: 2018-04-09

Publications

Background Pai CC, Chen M, Mirsoian A, Grossenbacher SK, Tellez J, Ames E, Sun K, Jagdeo J, Blazar BR, Murphy WJ, Abedi M. Treatment of chronic graft-versus-host disease with bortezomib. Blood. 2014 Sep 4;124(10):1677-88. doi: 10.1182/blood-2014-02-554279. Epub 2014 Jul 9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bortezomib	Small molecule	0.2 mg/m2	Subcutaneous
Subject	Bortezomib	Small molecule	0.4 mg/m2	Subcutaneous
Subject	Bortezomib	Small molecule	0.6 mg/m2	Subcutaneous
Subject	Bortezomib	Small molecule	0.8 mg/m2	Subcutaneous
Subject	Bortezomib	Small molecule	1 mg/m2	Subcutaneous
Subject	Bortezomib	Small molecule	1.2 mg/m2	Subcutaneous
Subject	Bortezomib	Small molecule	1.4 mg/m2	Subcutaneous
Subject	Bortezomib	Small molecule	1.6 mg/m2	Subcutaneous

Bortezomib in Patients With Chronic Graft Versus Host Disease

Summary

Timeline

Publications

Drugs

Indications